Search

Displaying results 3511 - 3520 of 6076 in total
  1. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  2. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    In rats, toxicity studies have so far shown favourable safety for this vaccine[L30653, L30658], Phase 1 trial is currently ongoing in Taiwan (NCT04545749). … In addition, the vaccine contains a proprietary peptide UBITh®1a for enhanced immunogenicity, five identified peptides with Th or CTL epitopes to improve peptide solubility, and aluminum phosphate adjuvant

  3. Drug

    Stem-cell derived exosome vesicle products

    go.drugbank.com/drugs/DB15743
    Experimental

    Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication.

  4. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

  5. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    However, there currently are no clinical indications for preferential use of ridogrel over aspirin. … Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  6. Drug

    Exemestane

    go.drugbank.com/drugs/DB00990
    ApprovedInvestigational

    Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the ...

  7. Drug

    Topsalysin

    go.drugbank.com/drugs/DB05160
    Investigational

    Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.

  8. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  9. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978] … ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

  10. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity.